🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dupilumab Therapy for EGIDs

Recruitingn/aAges 1 Year - 18 YearsAllChildren's Hospital of Fudan University
NCT07257835 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinical diagnosis of Refractory Peptic Ulcers * with Refractory Eosinophilic Gastrointestinal Disorders Exclusion Criteria: * with Active Helicobacter pylori infection at present. * with Inflammatory bowel disease * with Parasite infection * with Cancer
💊

What it tests

  • Dupilumab - Standard Dose
  • subcutaneous injection
📍

Where

1 site
201102
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy